Researchers examine the rise of artemisinin drug resistance in Eritrea - and search for its genetic basis.

Transcript

Artemisinin – a key antimalarial drug – and other drugs derived from it, are fast losing their effectiveness across South East Asia and increasingly in Africa, too. To investigate this, researchers conducted a review of drug efficacy studies in the East African country of Eritrea. They looked for the rates of delayed parasite clearance in the three days following treatment – a key marker of partial drug resistance. They found a troubling pattern: delayed parasite clearance climbed from 0.4% in 2016 to 1.9% in 2017, followed by a marked increase to 4.2% in 2019. By isolating and sequencing parasitic DNA, they found that this trend was associated with the rise of a novel mutation to the Kelch13 region of the parasite, called R622I. Given the lack of alternative drugs, the emergence of resistance in Africa is concerning.

Source

Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea

About The Podcast

The Johns Hopkins Malaria Minute podcast is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.